Differential cellular recognition pattern to M. tuberculosis targets defined by IFN-γ and IL-17 production in blood from TB + patients from Honduras as compared to health care workers: TB and immune responses in patients from Honduras

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Alvarez Corrales, Nancy ^a,b   Ahmed, Raija K ^c   Rodriguez, Carol A ^a   Balaji, Kithiganahalli N ^d   Rivera, Rebeca ^a   Sompallae, Ramakrishna ^e   Vudattu, Nalini K ^f   Hoffner, Sven E ^c   Zumla, Alimuddin ^g   Pineda Garcia, Lelany ^a   Maeurer, Markus ^b,h  

^a NATIONAL AUTONOMOUS UNIVERSITY OF HONDURAS   (Honduras)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Swedish Institute for Communicable Disease Control   (Sweden)

^d INDIAN INSTITUTE OF SCIENCE   (India)

^e UNIVERSITY OF IOWA   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antigen recognition; Biomarkers; M. tuberculosis; T cells; TB

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; MYCOBACTERIUM ANTIGEN;

ADULT; ANTIGEN RECOGNITION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HEALTH CARE PERSONNEL; HONDURAS; HUMAN; HUMAN CELL; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL;

BACTERIAL PROTEINS; COHORT STUDIES; FEMALE; HEALTH PERSONNEL; HONDURAS; HUMANS; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; INTERLEUKIN-17; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT PROTEINS; TUBERCULOSIS;

EID: 84874528365     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-125     Document Type: Article

References (73)

1. WHO Global TB Control 2010. Region of the Americas 2010, 2010: 99-120 ISBN 978 92 4 156406 9, http://www.doh.state.fl.us/disease_ctrl/tb/trends-stats/Fact-Sheets/US-Global/WHO_Report2010_Global_TB_Control.pdf., WHO.
2. WHO The global plan to Stop TB 2011-2015. Transforming the fight. 2011, WHO Stop TB Partnership, WHO.
3. PAHO Plan Regional de Tuberculosis 2006-2015. National Tuberculosis Control Programs, Ministries of Public Health 2006, Washington, DC: PAHO, 2006: 5-23 ISBN 92 75 12673 9, http://www.stoptb.org/assets/documents/global/plan/tb-reg-plan-2006-15%20AMRO.pdf., PAHO.
4. PortalSida Situación Epidemiológica Tuberculosis 2007, 1-2. Honduras: MCP Honduras, PortalSida.
5. WHO Tuberculosis profile 2011, Honduras: World Health Organization, WHO.
6. Varela Martinez C. Plan estratégico nacional para el control de la tuberculosi, PENTB 2009-2015. Resumen. Rev Med Hondur 2010, 78:1.
7. O'Grady J. New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr Opin Pulm Med 2011, 17(3):134-41. 10.1097/MCP.0b013e3283452346, 21415753.
8. McNerney R. Screening of immigrants in the UK for latent tuberculosis. Expert Rev Respir Med 2011, 5(4):483-6. 10.1586/ers.11.45, 21859267.
9. Ferrara G. A decade of interferon-gamma release assays: quest for the holy grail to diagnose latent infection with mycobacterium tuberculosis?. Am J Respir Crit Care Med 2011, 183(12):1732.
10. Curtis MM, Way SS. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology 2009, 126(2):177-85. 10.1111/j.1365-2567.2008.03017.x, 2632692, 19125888.
11. Kumar NP. Suppressed type 1, type 2, and type 17 cytokine responses in active tuberculosis in children. Clin Vaccine Immunol 2011, 18(11):1856-64. 10.1128/CVI.05366-11, 3209030, 21955625.
12. Kleinsteuber K. SOCS3 promotes interleukin-17 expression of human T cells. Blood 2012, 120(22):4374-82. 10.1182/blood-2011-11-392738, 23033269.
13. Hanekom WA, Abel B, Scriba TJ. Immunological protection against tuberculosis. S Afr Med J 2007, 97(10 Pt 2):973-7.
14. Kaufmann SH. How can immunology contribute to the control of tuberculosis?. Nat Rev Immunol 2001, 1(1):20-30. 10.1038/35095558, 11905811.
15. Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb) 2004, 84(1-2):93-101.
16. Demissie A. Recognition of stage specific Mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clinical and vaccine immunology 2005, 179-186.
17. Garnier T. The complete genome sequence of Mycobacterium bovis. Proc Natl Acad Sci USA 2003, 100(13):7877-82. 10.1073/pnas.1130426100, 164681, 12788972.
18. Cole ST. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393(6685):537-44. 10.1038/31159, 9634230.
19. Mathur M, Kolattukudy PE. Molecular cloning and sequencing of the gene for mycocerosic acid synthase, a novel fatty acid elongating multifunctional enzyme, from Mycobacterium tuberculosis var. bovis Bacillus Calmette-Guerin. J Biol Chem 1992, 267(27):19388-95.
20. Rainwater DL, Kolattukudy PE. Fatty acid biosynthesis in Mycobacterium tuberculosis var. bovis Bacillus Calmette-Guerin. Purification and characterization of a novel fatty acid synthase, mycocerosic acid synthase, which elongates n-fatty acyl-CoA with methylmalonyl-CoA. J Biol Chem 1985, 260(1):616-23.
21. Camus JC. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 2002, 148(Pt 10):2967-73.
22. Mawuenyega KG. Mycobacterium tuberculosis functional network analysis by global subcellular protein profiling. Mol Biol Cell 2005, 16(1):396-404. 539182, 15525680.
23. Gu S. Comprehensive proteomic profiling of the membrane constituents of a Mycobacterium tuberculosis strain. Mol Cell Proteomics 2003, 2(12):1284-96. 10.1074/mcp.M300060-MCP200, 14532352.
24. Fleischmann RD. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 2002, 184(19):5479-90. 10.1128/JB.184.19.5479-5490.2002, 135346, 12218036.
25. van Pittius NC G. Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions. BMC Evol Biol 2006, 6:95. 10.1186/1471-2148-6-95, 1660551, 17105670.
26. Singh KK. Immunogenicity of the Mycobacterium tuberculosis PPE55 (Rv3347c) protein during incipient and clinical tuberculosis. Infect Immun 2005, 73(8):5004-14. 10.1128/IAI.73.8.5004-5014.2005, 1201194, 16041015.
27. Guse A. Biochemical and structural analysis of the molybdenum cofactor biosynthesis protein MobA. J Biol Chem 2003, 278(28):25302-7. 10.1074/jbc.M302639200, 12719427.
28. De Wit L, Palou M, Content J. Nucleotide sequence of the 85B-protein gene of Mycobacterium bovis BCG and Mycobacterium tuberculosis. DNA Seq 1994, 4(4):267-70.
29. Harth G. Novel insights into the genetics, biochemistry, and immunocytochemistry of the 30-kilodalton major extracellular protein of Mycobacterium tuberculosis. Infect Immun 1996, 64(8):3038-47. 174185, 8757831.
30. Raman K, Yeturu K, Chandra N. targetTB: a target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis. BMC Syst Biol 2008, 2:109. 10.1186/1752-0509-2-109, 2651862, 19099550.
31. Anderson DH. An interfacial mechanism and a class of inhibitors inferred from two crystal structures of the Mycobacterium tuberculosis 30 kDa major secretory protein (Antigen 85B), a mycolyl transferase. J Mol Biol 2001, 307(2):671-81. 10.1006/jmbi.2001.4461, 11254389.
32. Steyn AJ, Joseph J, Bloom BR. Interaction of the sensor module of Mycobacterium tuberculosis H37Rv KdpD with members of the Lpr family. Mol Microbiol 2003, 47(4):1075-89. 10.1046/j.1365-2958.2003.03356.x, 12581360.
33. Perez E. Characterization of three glycosyltransferases involved in the biosynthesis of the phenolic glycolipid antigens from the Mycobacterium tuberculosis complex. J Biol Chem 2004, 279(41):42574-83. 10.1074/jbc.M406246200, 15292272.
34. Berg S. The glycosyltransferases of Mycobacterium tuberculosis - roles in the synthesis of arabinogalactan, lipoarabinomannan, and other glycoconjugates. Glycobiology 2007, 17(6):35-56R. 10.1093/glycob/cwm010, 17261566.
35. Banerjee S. Comparison of Mycobacterium tuberculosis isocitrate dehydrogenases (ICD-1 and ICD-2) reveals differences in coenzyme affinity, oligomeric state, pH tolerance and phylogenetic affiliation. BMC Biochem 2005, 6:20. 10.1186/1471-2091-6-20, 1260013, 16194279.
36. Malen H. Comprehensive analysis of exported proteins from Mycobacterium tuberculosis H37Rv. Proteomics 2007, 7(10):1702-18. 10.1002/pmic.200600853, 17443846.
37. Miller BH, Shinnick TM. Evaluation of Mycobacterium tuberculosis genes involved in resistance to killing by human macrophages. Infect Immun 2000, 68(1):387-90. 10.1128/IAI.68.1.387-390.2000, 97146, 10603413.
38. Armitige LY. Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages. Infect Immun 2000, 68(2):767-78. 10.1128/IAI.68.2.767-778.2000, 97204, 10639445.
39. Abou-Zeid C. Characterization of fibronectin-binding antigens released by Mycobacterium tuberculosis and Mycobacterium bovis BCG. Infect Immun 1988, 56(12):3046-51. 259698, 3141278.
40. Belisle JT. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 1997, 276(5317):1420-2. 10.1126/science.276.5317.1420, 9162010.
41. Wilkinson RJ. An increase in expression of a Mycobacterium tuberculosis mycolyl transferase gene (fbpB) occurs early after infection of human monocytes. Mol Microbiol 2001, 39(3):813-21. 10.1046/j.1365-2958.2001.02280.x, 11169120.
42. Borremans M. Cloning, sequence determination, and expression of a 32-kilodalton-protein gene of Mycobacterium tuberculosis. Infect Immun 1989, 57(10):3123-30. 260779, 2506131.
43. Ronning DR. Mycobacterium tuberculosis antigen 85A and 85C structures confirm binding orientation and conserved substrate specificity. J Biol Chem 2004, 279(35):36771-7. 10.1074/jbc.M400811200, 15192106.
44. Braunstein M. Identification of genes encoding exported Mycobacterium tuberculosis proteins using a Tn552'phoA in vitro transposition system. J Bacteriol 2000, 182(10):2732-40. 10.1128/JB.182.10.2732-2740.2000, 101980, 10781540.
45. Garbe TR, Hibler NS, Deretic V. Isoniazid induces expression of the antigen 85 complex in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996, 40(7):1754-6. 163413, 8807080.
46. Sorensen AL. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun 1995, 63(5):1710-7. 173214, 7729876.
47. Berthet FX. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 1998, 144(Pt 11):3195-203.
48. Fortune SM. Mutually dependent secretion of proteins required for mycobacterial virulence. Proc Natl Acad Sci USA 2005, 102(30):10676-81. 10.1073/pnas.0504922102, 1176248, 16030141.
49. Brodin P. Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. Infect Immun 2006, 74(1):88-98. 10.1128/IAI.74.1.88-98.2006, 1346617, 16368961.
50. DiGiuseppe Champion PA. ESX-1 secreted virulence factors are recognized by multiple cytosolic AAA ATPases in pathogenic mycobacteria. Mol Microbiol 2009, 73(5):950-62. 10.1111/j.1365-2958.2009.06821.x, 3023814, 19682254.
51. Guinn KM. Individual RD1-region genes are required for export of ESAT-6/CFP-10 and for virulence of Mycobacterium tuberculosis. Mol Microbiol 2004, 51(2):359-70. 10.1046/j.1365-2958.2003.03844.x, 1458497, 14756778.
52. Renshaw PS. Conclusive evidence that the major T-cell antigens of the Mycobacterium tuberculosis complex ESAT-6 and CFP-10 form a tight, 1:1 complex and characterization of the structural properties of ESAT-6, CFP-10, and the ESAT-6*CFP-10 complex. Implications for pathogenesis and virulence. J Biol Chem 2002, 277(24):21598-603. 10.1074/jbc.M201625200, 11940590.
53. Singh A. Dissecting virulence pathways of Mycobacterium tuberculosis through protein-protein association. Proc Natl Acad Sci USA 2006, 103(30):11346-51. 10.1073/pnas.0602817103, 1544089, 16844784.
54. Renshaw PS. Structure and function of the complex formed by the tuberculosis virulence factors CFP-10 and ESAT-6. EMBO J 2005, 24(14):2491-8. 10.1038/sj.emboj.7600732, 1176459, 15973432.
55. Narayana Y. Differential B-cell responses are induced by Mycobacterium tuberculosis PE antigens Rv1169c, Rv0978c, and Rv1818c. Clin Vaccine Immunol 2007, 14(10):1334-41. 10.1128/CVI.00181-07, 2168116, 17687113.
56. Adindla S, Guruprasad L. Sequence analysis corresponding to the PPE and PE proteins in Mycobacterium tuberculosis and other genomes. J Biosci 2003, 28(2):169-79. 10.1007/BF02706216, 12711809.
57. Sampson SL. Expression, characterization and subcellular localization of the Mycobacterium tuberculosis PPE gene Rv1917c. Tuberculosis (Edinb) 2001, 81(5-6):305-17.
58. Skjot RL. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun 2000, 68(1):214-20. 10.1128/IAI.68.1.214-220.2000, 97123, 10603390.
59. Majlessi L. CD8 + -T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family. Infect Immun 2003, 71(12):7173-7. 10.1128/IAI.71.12.7173-7177.2003, 308897, 14638811.
60. Okkels LM, Andersen P. Protein-protein interactions of proteins from the ESAT-6 family of Mycobacterium tuberculosis. J Bacteriol 2004, 186(8):2487-91. 10.1128/JB.186.8.2487-2491.2004, 412125, 15060053.
61. Lightbody KL. Characterisation of complex formation between members of the Mycobacterium tuberculosis complex CFP-10/ESAT-6 protein family: towards an understanding of the rules governing complex formation and thereby functional flexibility. FEMS Microbiol Lett 2004, 238(1):255-62.
62. Bansal K. PE_PGRS antigens of Mycobacterium tuberculosis induce maturation and activation of human dendritic cells. J Immunol 2010, 184(7):3495-504. 10.4049/jimmunol.0903299, 20176745.
63. Bansal K. Src homology 3-interacting domain of Rv1917c of Mycobacterium tuberculosis induces selective maturation of human dendritic cells by regulating PI3K-MAPK-NF-kappaB signaling and drives Th2 immune responses. J Biol Chem 2010, 285(47):36511-22. 10.1074/jbc.M110.158055, 2978579, 20837474.
64. Chaturvedi R. The multifunctional PE_PGRS11 protein from Mycobacterium tuberculosis plays a role in regulating resistance to oxidative stress. J Biol Chem 2010, 285(40):30389-403. 10.1074/jbc.M110.135251, 2945531, 20558725.
65. FDA Products and medical procedures. Devices approvals and clearances Food and Drug Administration, FDA.
66. WHO Manual para el diagnóstico bacteriológico de la tuberculosis. Normas y guia técnica 2008, WHO, WHO.
67. Sutherland JS. Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort. PLoS One 2010, 5(8):e12365. 10.1371/journal.pone.0012365, 2927558, 20811496.
68. Torrado E, Cooper AM. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev 2010, 21(6):455-62. 10.1016/j.cytogfr.2010.10.004, 3032416, 21075039.
69. Desel C. Recombinant BCG DeltaureC hly + induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 2011, 204(10):1573-84. 10.1093/infdis/jir592, 3192191, 21933877.
70. Ahmed RK. Pattern recognition and cellular immune responses to novel Mycobacterium tuberculosis-antigens in individuals from Belarus. BMC Infect Dis 2012, 12:41. 10.1186/1471-2334-12-41, 3305616, 22336002.
71. Brosch R. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 2007, 104(13):5596-601. 10.1073/pnas.0700869104, 1838518, 17372194.
72. Borgstrom E. Detection of proliferative responses to ESAT-6 and CFP-10 by FASCIA assay for diagnosis of Mycobacterium tuberculosis infection. J Immunol Methods 2011, 370(1-2):55-64.
73. Korn T. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517. 10.1146/annurev.immunol.021908.132710, 19132915.